World Health Organization Issues Warning Over Critical Lack of Weight-Loss Jabs

Fewer than 10% of patients eligible to benefit from weight-loss injections such as Wegovy have access to them, caution the WHO as it publishes its first advice on the therapies.

Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable access to this class of drugs.

According to estimates, over two billion will be living with obesity by 2030 without intervention.

"The latest guidelines acknowledges that excess weight is a long-term condition that can be managed with thorough and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are major hurdles to broad availability to the jabs that can help people shift significant body mass, says the agency.

Skinny Jab Shortage

Despite the current most favorable scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – under 10% of eligible patients, as stated by the health organization.

The recommendation encourages governments and firms to expand access, through approaches including voluntary licensing.

The intellectual property rights on a key compound – the core component of the drug Wegovy – is scheduled to end in multiple nations in 2026.

How Obesity Jabs Operate

The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so individuals eat less.

People typically begin shedding pounds after several weeks of commencing the weekly injections.

Evidence suggests users may see weight return a year later of discontinuing the drug, because their usual food cravings resume.

Being carrying excess weight increases your risk for developing health problems, such as diabetes, cardiovascular issues, brain attack, and certain cancers.

Excess weight concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, according to the WHO.